Medical Cannabis Relieves Behavioral and Psychological Symptoms of Alzheimer’s Dementia

Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer’s disease (AD).
Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability,
apathy, sleep and caregiver distress.
Conclusion: Adding MCO to AD patients’ pharmacotherapy is safe and a promising treatment option.

Authors: A Shelef, Y Barak, U Berger, D Paleacu, S Tadger, I Plopsky, Y Baruch

Journal of Alzheimer’s Disease (2016) 51: 15 – 19

Clinical Trials, Studies and Publications (click to access):

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study